FindTrial
Sign In

MAFLD and Sarcopenia and heart disease risk

A study of association of Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD) and dynapenia/sarcopenia with cardio-metabolic risks

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/04/042201
Enrollment
1100
Registered
2022-04-27
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E888- Other specified metabolic disorders

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

ICMR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adults of age 18-60 years, with fatty liver disease Obese/Overweight individuals Type 2 Diabetes Mellitus Metabolically dysregulated Lean body individuals Hand grip strength Men Appendicular skeletal muscle mass/height2 : Men SPPB=8 (The maximum score on the SPPB is:12) 4-minute gait speed

Exclusion criteria

Exclusion criteria: Pregnant women Patient denying consent Cirrhotic liver disease patients Pediatric population

Design outcomes

Primary

MeasureTime frame
ASCVD risk score, Prevalence of dynapenia and sarcopenia in MAFLD subjects. • metabolic parameters, insulin resistance and subclinical inflammationTimepoint: one time study—

Secondary

MeasureTime frame
metabolic parameters, insulin resistance and subclinical inflammation Timepoint: ONE TIME—

Countries

India

Contacts

Public ContactDr Naval Kishore Vikram

AIIMS, New Delhi

navalvikram@gmail.com01126593678

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026